Because increased MIF secretion promotes tumor cell survival, inflammation, and angiogenic complications, these reports highlight the benefits of adjuvant MIF inhibition to exhibit the full potential of anti-cancer therapy [5,24]. The gene discussed is MIF; the disease is cancer.